Medifast (MED) Getting Somewhat Positive Media Coverage, Report Shows
Media headlines about Medifast (NYSE:MED) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies negative and positive media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Medifast earned a media sentiment score of 0.20 on Accern’s scale. Accern also assigned news stories about the specialty retailer an impact score of 46.2553380095549 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the news stories that may have impacted Accern Sentiment Analysis’s analysis:
- Medifast stock skyrockets 13 percent to $50 per share after earnings beat Wall Street estimates (finance.yahoo.com)
- Medifast, Inc.: Gathering momentum, can it sustain its performance? (finance.yahoo.com)
- Medifast’s 2Q revenue exceeds expectations (thedailyrecord.com)
- Medifast Q2 2017 Revenue Exceeds Company Guidance (directsellingnews.com)
- Edited Transcript of MED earnings conference call or presentation 8-Aug-17 8:30pm GMT (finance.yahoo.com)
Medifast (MED) traded up 2.25% during mid-day trading on Friday, reaching $50.87. The company’s stock had a trading volume of 174,473 shares. Medifast has a one year low of $35.55 and a one year high of $51.07. The stock has a 50-day moving average price of $42.47 and a 200-day moving average price of $43.33. The company has a market capitalization of $606.88 million, a price-to-earnings ratio of 25.56 and a beta of 0.48.
Medifast (NYSE:MED) last issued its earnings results on Tuesday, August 8th. The specialty retailer reported $0.63 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.53 by $0.10. The company had revenue of $75.70 million during the quarter, compared to analyst estimates of $71.96 million. Medifast had a return on equity of 29.92% and a net margin of 10.01%. The firm’s quarterly revenue was up 6.5% on a year-over-year basis. During the same quarter last year, the business posted $0.63 EPS. Equities research analysts forecast that Medifast will post $2.12 EPS for the current year.
The company also recently announced a quarterly dividend, which was paid on Wednesday, August 9th. Investors of record on Friday, June 23rd were paid a $0.32 dividend. The ex-dividend date was Wednesday, June 21st. This represents a $1.28 dividend on an annualized basis and a yield of 2.52%. Medifast’s dividend payout ratio (DPR) is 64.32%.
Several brokerages recently commented on MED. BidaskClub raised Medifast from a “strong sell” rating to a “sell” rating in a report on Friday. Sidoti lowered Medifast from a “buy” rating to a “neutral” rating in a report on Tuesday, May 2nd.
Medifast, Inc is engaged in the production, distribution and sale of weight loss, weight management and healthy living products, and other consumable health and nutritional products. Medifast product lines include weight loss, weight management, and healthy living meal replacements, snacks, hydration products and vitamins.
Receive News & Ratings for Medifast Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medifast Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.